The Efficacy and Safety of Cuttlebone for Lowering Serum Phosphate in Patients with End-stage Renal Disease: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Front Pharmacol

Date 2023 Aug 9

PMID 37554990

Authors

Hsiao-Tien Chen

Kuo-Chuan Hung

Chin-Wei Hsu

Jui-Yi Chen

Chien-Cheng Liu

I-Wen Chen

Cheuk-Kwan Sun

Affiliations

Soon will be listed here.

Abstract

The efficacy of cuttlebone for treating hyperphosphatemia in patients with end-stage renal disease and its safety remained unclear. Randomized controlled trials comparing the efficacy of cuttlebone with conventional interventions were retrieved from MEDLINE, EMBASE, Cochrane Library, Airiti Library, and other major Chinese databases until 1 February 2023. The primary outcome was circulating phosphate concentration, while secondary outcomes included circulating calcium and intact parathyroid hormone levels, calcium-phosphorus product, and treatment-related side-effects. Analysis of nine studies published between 2000 and 2019 including 726 participants showed a lower circulating phosphate concentration in the cuttlebone group than in controls [mean difference (MD) = -0.23, 95% CI: -0.39 to -0.06, = 0.006, I = 94%, 726 patients] and a dose-dependent effect of cuttlebone against hyperphosphatemia. Therapeutic benefits were noted after both short-term (1-2 months) and long-term (3-6 months) treatments. Besides, patients receiving hemodialysis showed a better response to cuttlebone than those receiving peritoneal dialysis. There was no difference in circulating calcium level (mean difference = 0.03, 95% CI: -0.01 to 0.07, = 0.17, I = 34%, 654 patients), while patients receiving cuttlebone showed lower circulating iPTH level and calcium-phosphorus product (MD = -43.63, 95% CI: -74.1 to -13.16, = 0.005, I = 76%, 654 patients), (MD = -0.38, 95% CI: -0.38 to -0.01, = 0.04, I = 83%, 520 patients). No difference in the risks of constipation, gastrointestinal discomfort, and elevated blood calcium was noted between the two groups. Compared with conventional phosphate-binding agents, cuttlebone more efficiently suppressed hyperphosphatemia with a dose-dependent effect. The limited number of included studies warrants further clinical investigations to verify our findings. https://www.crd.york.ac.uk/prospero/, identifier CRD42023396300.

References

Holden R, Mustafa R, Alexander R, Battistella M, Bevilacqua M, Knoll G . Canadian Society of Nephrology Commentary on the Kidney Disease Improving Global Outcomes 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. Can J Kidney Health Dis. 2020; 7:2054358120944271. PMC: 7412914. DOI: 10.1177/2054358120944271. View

Palaveniene A, Harkavenko V, Kharchenko V, Daugela P, Pranskunas M, Juodzbalys G . Cuttlebone as a Marine-Derived Material for Preparing Bone Grafts. Mar Biotechnol (NY). 2018; 20(3):363-374. DOI: 10.1007/s10126-018-9816-6. View

Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey N, Drueke T . Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005; 67(3):1062-9. DOI: 10.1111/j.1523-1755.2005.00171.x. View

Gutierrez O, Wolf M . Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Semin Dial. 2010; 23(4):401-6. DOI: 10.1111/j.1525-139X.2010.00750.x. View

. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2019; 7(1):1-59. PMC: 6340919. DOI: 10.1016/j.kisu.2017.04.001. View

Thongprayoon C, Cheungpasitporn W, Mao M, Harrison A, Erickson S . Elevated admission serum calcium phosphate product as an independent risk factor for acute kidney injury in hospitalized patients. Hosp Pract (1995). 2019; 47(2):73-79. DOI: 10.1080/21548331.2019.1568719. View

Jamal S, Vandermeer B, Raggi P, Mendelssohn D, Chatterley T, Dorgan M . Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013; 382(9900):1268-77. DOI: 10.1016/S0140-6736(13)60897-1. View

Baek J, Park H, Kim K, Chun S, Kim B . Marine Plankton-Derived Whitlockite Powder-Based 3D-Printed Porous Scaffold for Bone Tissue Engineering. Materials (Basel). 2022; 15(10). PMC: 9147529. DOI: 10.3390/ma15103413. View

Zhou C, Shi Z, Ouyang N, Ruan X . Hyperphosphatemia and Cardiovascular Disease. Front Cell Dev Biol. 2021; 9:644363. PMC: 7970112. DOI: 10.3389/fcell.2021.644363. View

10.

Evenepoel P, Meijers B, Bammens B, Viaene L, Claes K, Sprangers B . Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. Nephrol Dial Transplant. 2016; 31(9):1508-14. DOI: 10.1093/ndt/gfv414. View

11.

Shaman A, Kowalski S . Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi Pharm J. 2016; 24(4):494-505. PMC: 4908098. DOI: 10.1016/j.jsps.2015.01.009. View

12.

Yee-Moon Wang A, Pasch A, Wong C, Chu I, Tang T, Chu J . Long-Term Effects of Sevelamer on Vascular Calcification, Arterial Stiffness, and Calcification Propensity in Patients Receiving Peritoneal Dialysis: The Randomized Pilot SERENE (Sevelamer on Vascular Calcification, Arterial Stiffness) Trial. Kidney Med. 2022; 4(2):100384. PMC: 8861951. DOI: 10.1016/j.xkme.2021.10.002. View

13.

Ruospo M, Palmer S, Natale P, Craig J, Vecchio M, Elder G . Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018; 8:CD006023. PMC: 6513594. DOI: 10.1002/14651858.CD006023.pub3. View

14.

Pazianas M, Miller P . Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021; 78(4):582-589. DOI: 10.1053/j.ajkd.2020.12.024. View

15.

Xu Y, Ye J, Zhou D, Su L . Research progress on applications of calcium derived from marine organisms. Sci Rep. 2020; 10(1):18425. PMC: 7595125. DOI: 10.1038/s41598-020-75575-8. View

16.

Kang H, Seo C, Park Y . The effects of marine carbohydrates and glycosylated compounds on human health. Int J Mol Sci. 2015; 16(3):6018-56. PMC: 4394518. DOI: 10.3390/ijms16036018. View

17.

Elder G, Center J . The role of calcium and non calcium-based phosphate binders in chronic kidney disease. Nephrology (Carlton). 2017; 22 Suppl 2:42-46. DOI: 10.1111/nep.13031. View

18.

Lim S, Lee K, Kang T . Chitin from Cuttlebone Activates Inflammatory Cells to Enhance the Cell Migration. Biomol Ther (Seoul). 2015; 23(4):333-8. PMC: 4489827. DOI: 10.4062/biomolther.2015.062. View

19.

Huang X, Nie S, Xie M . Interaction between gut immunity and polysaccharides. Crit Rev Food Sci Nutr. 2015; 57(14):2943-2955. DOI: 10.1080/10408398.2015.1079165. View

20.

Brown-Tortorici A, Narasaki Y, You A, Norris K, Streja E, Peralta R . The Interplay between Dietary Phosphorous, Protein Intake, and Mortality in a Prospective Hemodialysis Cohort. Nutrients. 2022; 14(15). PMC: 9330827. DOI: 10.3390/nu14153070. View